Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 10/20 | 0.54 |
| ▸ | MGAM | O43451 | 9/20 | 0.54 |
| ▸ | AMY1A | P0DUB6 | 9/20 | 0.54 |
| ▸ | SI | P14410 | 9/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 9/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204056 | 0.88 | MGAM (0.54) | KMOGAAMGAMAMY1ASI | |
| SCHEMBL27033668 | 0.86 | KMO (0.74) | KMOGAAMGAMAMY1ASI | |
| SCHEMBL27033558 | 0.82 | KMO (0.56) | KMOGAAMGAMAMY1ASI | |
| SCHEMBL1689837 | 0.78 | GAA (0.67) | GAAMGAMAMY1ASIMGAM2 | |
| Ethyl Bromo Acetate SCHEMBL29174319 | 0.77 | KMO (0.51) | KMOGAAMGAMAMY1ASI | |
| SCHEMBL11796203 | 0.74 | KMO (0.57) | KMOGAAMGAMAMY1ASI | |
| SCHEMBL204001 | 0.72 | KMO (0.55) | KMOGAAMGAMAMY1ASI | |
| SCHEMBL17103035 | 0.72 | SLC9A1 (0.64) | KMOGAAMGAMAMY1ASI | |
| SCHEMBL27380658 | 0.71 | KMO (0.57) | KMOGAAMGAMAMY1ASI | |
| SCHEMBL17103012 | 0.71 | KMO (0.61) | KMOGAAMGAMAMY1ASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3428148-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3498696-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARASITICIDAL COMPOUNDS | Merial, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3428148-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3050874-B1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL INC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3088384-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2010056999-A9 | ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL LIMITED (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-3088384-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2155699-B9 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3050874-A1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | Merial, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2639228-B1 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL INC (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2010056999-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL LIMITED (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2010-05-20 | — | — | US | disclosed |
| EP-2155699-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial Limited (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008144275-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2008-11-27 | — | — | WO | disclosed |
| EP-1539719-B1 | BENZOTRIAZOL-1-YLAMINO-ACETONITRILE COMPOUNDS AND THE USE THEREOF IN PEST CONTROL | NOVARTIS AG (CH) | 2007-08-15 | — | — | EP | disclosed |
| US-7084280-B2 | Benzotriazol-1-yl-aminoacetonitrile compounds and their use in the control of parasite disease | NOVARTIS ANIMAL HEALTH US, INC. | 2006-08-01 | — | — | US | disclosed |
| US-20050272935-A1 | Organic compounds | NOVARTIS ANIMAL HEALTH US, INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1539719-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024704-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | KMO 16/4885GAA 1853/4885MGAM 2748/4885 |
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4B1, NPY4R, CYP4X1 | KMO 95/4885GAA 2591/4885MGAM 3356/4885 |
| US-20050272935-A1 | Organic compounds | ACHE, DDT, TYR | KMO 682/4885GAA 2198/4885MGAM 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.